Filing summary: Global Medical REIT Inc. (NYSE: GMRE)
Entity note: The request identifies Chiron Real Estate Inc., but the supplied Form 10-K is for Global Medical REIT Inc. This summary reflects the filing provided, not the named company.
Business context and reporting period
The filing reports the fiscal year ended December 31, 2020; it is an annual report, not a standalone fourth-quarter filing. Global Medical REIT acquires purpose-built healthcare facilities and leases them primarily to healthcare systems and physician groups, generally under triple-net leases. At year-end it owned 86 facilities with 3.7 million leasable square feet and approximately $87.6 million in annualized base rent.
Key financial metrics
| Metric | 2020 | 2019 |
|---|---|---|
| Total revenue | $93.7 million | $70.7 million |
| Net income (loss) | $(2.5) million | $9.6 million |
| Net income (loss) attributable to common stockholders | $(7.7) million; $(0.17) per share | $3.4 million; $0.10 per share |
| FFO per share and unit | $0.56 | $0.75 |
| AFFO per share and unit | $0.88 | $0.75 |
| Net cash from operating activities | $34.5 million | $36.4 million |
| Net cash used in investing activities | $(223.7) million | $(258.2) million |
| Net cash from financing activities | $192.7 million | $224.1 million |
| Total debt, net | $586.6 million | $386.2 million |
| Cash and restricted cash | $10.8 million | $7.2 million |
Revenue increased 32.5%, mainly from acquisitions and a full year of rent from 2019 acquisitions. Expenses rose to $96.2 million from $61.1 million. The company completed 18 acquisitions for a contractual purchase price of $226.5 million and raised $54.5 million gross through ATM common-stock sales. Common dividends remained $0.80 per share for the year; preferred dividends were $5.8 million.
Material changes and unusual items
- On July 9, 2020, the company internalized its external manager, acquiring its parent for $17.7 million after a working-capital adjustment. The transaction included $14.0 million of expense: $12.1 million for settlement of the prior management agreement and $1.9 million of transaction-related professional fees.
- The internalization charge was a major contributor to the swing from 2019 GAAP net income to a 2020 GAAP net loss. AFFO, a non-GAAP measure, excludes internalization costs; 2020 AFFO was $43.9 million versus $28.4 million in 2019. FFO declined to $28.0 million from $28.4 million.
- Common shares outstanding rose from 43.8 million at 2019 year-end to 49.5 million at 2020 year-end, primarily reflecting equity issuance and unit redemptions.
- Net debt increased substantially to fund acquisitions. The weighted-average debt rate at year-end was 3.17%, versus 3.90% a year earlier. $350 million of term-loan exposure was hedged; $175.2 million of revolver borrowings remained unhedged and floating-rate.
Liquidity, outlook, risks, and contingencies
Management said COVID-19 did not materially affect 2020 results, liquidity, or capital resources, but noted the outlook remained uncertain. Rent deferrals totaled $1.1 million, of which $0.1 million remained outstanding at year-end; the company also recognized reserves for approximately $1.4 million of rent, including $0.4 million of deferred rent. As of February 28, 2021, cash and available revolver capacity totaled approximately $85 million. Management believed existing cash and operating cash flow could meet short-term needs under then-current deferral levels, while growth and longer-term needs depend partly on continued debt and equity-market access.
- Credit facility capacity was $600 million, including a $350 million term loan, a $250 million revolver and a remaining $50 million accordion. The revolver expires in August 2022, with a company-controlled one-year extension option; the term loan matures in August 2023. The company reported compliance with covenants at year-end, including a limit on distributions to 95% of AFFO.
- Interest-rate risk is material: a 100-basis-point LIBOR increase on year-end unhedged variable-rate debt was estimated to reduce annual cash flow by approximately $1.8 million. LIBOR transition and swap-contract changes were also identified as risks.
- Key business risks include tenant ability to pay rent, dependence on single-tenant facilities, healthcare reimbursement and regulatory changes, geographic concentration, refinancing and covenant risk, and further COVID-19 disruption. The three largest tenants represented about 20% of annualized base rent; Texas was the largest state concentration at 18%.
- Management cited aging demographics, healthcare spending growth and a shift toward outpatient care as potential long-term demand drivers. No formal earnings or acquisition guidance was provided. As of March 3, 2021, six properties were under contract for approximately $75.7 million, subject to due diligence. Three post-year-end acquisitions totaling $25.4 million and $2.0 million of annualized base rent had closed.
- There was no material litigation reported. The independent auditor gave an unqualified opinion on the financial statements and internal controls; management also concluded disclosure controls and internal control over financial reporting were effective.
Most important facts for investors to verify
- Confirm the intended issuer: the supplied filing is for Global Medical REIT Inc., not Chiron Real Estate Inc.
- Review tenant rent collections, deferred-rent repayment, and whether tenant reserves or write-offs grow as pandemic effects continue.
- Assess debt maturities, covenant headroom, revolver availability, unhedged floating-rate exposure, and the LIBOR-to-replacement-rate transition.
- Evaluate the sustainability of the $0.80 common dividend against AFFO, cash flow, capital needs, and the 95% AFFO distribution covenant; note the filing declared $0.205 per common share for first-quarter 2021.
- Examine acquisition underwriting, the pending-property pipeline, share issuance and dilution, and the quality and comparability of management’s non-GAAP FFO and AFFO measures.